|5.||Coronary Artery Disease (Coronary Atherosclerosis)
|1.||Serruys, Patrick W: 58 articles (12/2015 - 09/2003)|
|2.||Stone, Gregg W: 55 articles (12/2015 - 12/2003)|
|3.||Windecker, Stephan: 45 articles (10/2015 - 11/2002)|
|4.||Xu, Bo: 39 articles (12/2015 - 01/2006)|
|5.||Colombo, Antonio: 32 articles (02/2015 - 08/2002)|
|6.||Kim, Hyo-Soo: 31 articles (08/2015 - 04/2010)|
|7.||Jeong, Myung Ho: 31 articles (07/2015 - 09/2003)|
|8.||Thuesen, Leif: 29 articles (06/2014 - 02/2006)|
|9.||Thayssen, Per: 26 articles (12/2015 - 10/2006)|
|10.||Cutlip, Donald E: 26 articles (02/2015 - 10/2007)|
|1.||glucuronyl glucosamine glycan sulfate (Vessel)IBA
12/01/2008 - "No statistical difference between BMS and DES groups in the rate of cardiac death (6% vs. 9%, P = 0.56), STEMI or NSEMI (1.6% vs. 1.3% respectively, P = 0.88) and composite end point (13% vs. 10%, P = 0.65) was observed while a significant reduction in target vessel revascularization was seen in DES group (6% vs. 0% respectively, P = 0.02) was noticed. "
12/01/2004 - "Improved tissue level reperfusion did not translate into a significant reduction of cardiac mortality or the incidence of the combined endpoint consisting of cardiac death, nonfatal reinfarction and need for target vessel revascularisation during 30 day- and long-term follow-up (mean 274 days). "
01/01/2015 - "Target vessel failure (TVF), the primary composite endpoint of the trial, was defined as cardiac death, target vessel-related MI, or target vessel revascularization. "
12/01/2015 - "The 1-year target lesion failure rate, defined as the composite of cardiac death, target-vessel MI and target lesion revascularization was 1.9%. "
10/01/2015 - "Among all LST/VLST patients, in-hospital mortality (12.3%) and post-hospital target vessel failure (TVF) or cardiac death (21.7%, median follow-up 1.6 years) remained high. "
05/01/2010 - "It is my personal opinion that in such circumstances after cardiac death (DCD) will allow at best only the retrieval of few marginal kidneys and some tissues, and therefore will not be very helpful for our waiting list patients. "
10/01/2015 - "In recent years, novel strategies have been developed to increase the donor lung pool: improved donor management, the use of lungs from donations after cardiac death (DCD), the use of lobar lung living-donors (LLLD) and the use of ex-vivo lung perfusion (EVLP) to assess and repair injured donor lungs. "
01/01/2014 - "The purpose of this study was to examine the effects of MO on the short-term outcomes of kidneys transplanted from donation after cardiac death (DCD) donors. "
11/27/2012 - "This study investigated whether short-term HMP could improve the quality of lungs donated after cardiac death (DCD). "
09/01/2012 - "Efforts to characterize donation after cardiac death (DCD) have included studies of cell viability, histological and immunohistochemical changes, and oxidative stress, which is known to negatively impact graft survival. "
01/01/2015 - "Long-term statin therapy dramatically reduced the rates of both MACE and all-cause death/cardiac death (by 20.5% and 28.6%/27.7%, resp.) in CAD and CKD patients. "
05/01/2005 - "At follow up, group 1 had improved global LV ejection fraction (48.7% v 43.6%, p < 0.001) and LV indexed end diastolic and end systolic volumes (75 v 86 ml/m(2) and 40 v 53 ml/m(2), respectively, p = 0.011) compared with group 2. Kaplan-Meier analysis showed a higher incidence of cardiac death (p = 0.02) and MACE (p < 0.0001) in group 2. TIMI 3 after PTCA was an independent predictor of event-free survival at follow up. "
02/01/2011 - "In a large observational registry with admitted potential for selection bias and residual confounding, DES in DM patients with coronary bifurcation lesions were associated with improved outcomes in terms of MACE, cardiac death, and repeat revascularization at long-term follow up. "
01/01/2009 - "MACE [cardiac death (CD) and hospitalization for angina (HA)] were the study end points. "
01/15/2016 - "At 9months, the TLR rate was 7.0% (13/187) whereas the rates for MACE, MI and cardiac death were 10.7% (20/187), 4.8% (9/187) and 2.1% (4/187) respectively. "
07/01/2005 - "Dobutamine stress echocardiography and SPECT are equally effective in predicting long-term cardiac death in both normotensive and hypertensive patients."
04/01/1997 - "By multivariate regression analysis, positive results on dobutamine echocardiography remained independently predictive of future cardiac death after left ventricular ejection fraction and other clinical variables were accounted for. "
08/01/2012 - "Importantly, treated mice became more resistant to dobutamine-induced cardiac death. "
10/01/2011 - "Furthermore, AAV-microdystrophin therapy prevented dobutamine-stress induced acute cardiac death. "
07/01/2010 - "Three hundred fifty-three participants with a mean+/-SD age of 64+/-12 years (54%men) underwent dobutamine cardiovascular magnetic resonance stress testing and then were followed up for 6+/-2 years (mean+/-SD; range, 0.5-11.5) to assess the post-dobutamine cardiovascular magnetic resonance stress test occurrence of MI or cardiac death. "
04/01/1999 - "The Lescol in Symptomatic Angina study found reductions in all cardiac events or cardiac death in patients after 1 year of fluvastatin 40 mg/day (1.6% vs 5.6% for placebo, p < 0.05). "
06/01/2009 - "Fluvastatin was prescribed in a fixed dose of 80 mg. The primary end point was the composite of 30-day cardiac death and MI. "
09/01/2005 - "The key determinants of cost-effectiveness included the probabilities of repeat interventions, cardiac death, the cost of fluvastatin, and the time horizon used for the evaluation. "
01/01/2004 - "Fluvastatin treatment significantly prolonged the time to cardiac death (p = 0.0174) and the time to cardiac death or nonfatal MI (p = 0.0055) compared with placebo. "
09/01/2005 - "The Lescol Intervention Prevention Study (LIPS) was a multinational randomized controlled trial that showed a 47% reduction in the relative risk of cardiac death and a 22% reduction in major adverse cardiac events (MACEs) from the routine use of fluvastatin, compared with controls, in patients undergoing percutaneous coronary intervention (PCI, defined as angioplasty with or without stents). "
|6.||Dipyridamole (Persantine)FDA LinkGeneric
06/01/1997 - "The prognostic impact of dipyridamole stress echo has also been proven for presentation of hard end-points such as cardiac death. "
01/01/1997 - "When cardiac death was considered as the only significant event, with multivariate analysis, peak dipyridamole Wall Motion Score Index was the only significant predictor (chi 2 = 5.66; p = 0.013; relative risk estimate = 4.7; confidence intervals = 1.35-16.08). "
09/01/2002 - "The purpose of this study was to conduct a metaanalysis of semiquantitive dipyridamole myocardial perfusion scintigraphy for the prediction of perioperative myocardial infarction and cardiac death in patients undergoing noncardiac vascular surgery. "
06/01/1992 - "Cardiac death or nonfatal myocardial infarction occurred in only 7 (5%) of 150 patients with a normal dipyridamole thallium-201 study (p less than 0.001). "
07/01/1997 - "Adverse cardiac events (unstable angina, recurrent MI, or cardiac death) were evaluated during and 24 hours after the dipyridamole infusion and during the corresponding 24 hours for the control group. "
|7.||Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA
06/01/2012 - "marine omega-3 fatty acids are effective in preventing cardiovascular events, cardiac death and coronary events, especially in persons with high cardiovascular risk."
01/01/2014 - "Omega-3 fatty acids are known to prevent cardiac death. "
07/01/2013 - "Interaction between dietary marine-derived n-3 fatty acids intake and J-point elevation on the risk of cardiac death: a 24-year follow-up of Japanese men."
11/08/2011 - "Overall, current data provide strong concordant evidence that n-3 PUFA are bioactive compounds that reduce risk of cardiac death. "
05/01/2006 - "Initial epidemiological, clinical trial and animal data have suggested that a diet high in omega-3 fatty acids reduces the risk of cardiac death and that this reduction in the risk was owing to the prevention of fatal arrhythmias. "
|8.||Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
01/01/2006 - "Aspirin treatment at the time of PCI significantly reduced the risk of death from any cause and cardiac death. "
12/07/1996 - "After 30 days cardiac death or reinfarction, occurred in 11.0% (57/517) of the patients treated with anticoagulation and 11.2% (58/519) of the patients treated with aspirin (odds ratio 1.02, 95% confidence interval 0.69 to 1.50, P = 0.92). "
08/01/1996 - "Cardiac death rate was markedly reduced: 1.6% for aspirin users and 5.4% for nonusers (p = 0.005). "
10/01/1994 - "Aspirin has been shown to reduce the risk of further cardiovascular events or cardiac death in patients identified as at high risk. "
11/28/1985 - "The corresponding figures for either cardiac death alone or death from any cause were 3.0 per cent in the groups given aspirin and 11.7 per cent in the other groups, representing a risk reduction of 71 per cent (P = 0.004). "
|9.||Atrial Natriuretic Factor (ANF)IBA
10/01/2001 - "The area under the receiver operator characteristic (ROC) curve for the cTnT as predictor of both overall and cardiac death was significantly greater than the area under the cTnI curve (p < 0.0001 and p = 0.01), the BNP curve (p < 0.001 and p < 0.01) or the ANP curve (p < 0.0001 and p < 0.005). "
01/01/2003 - "Post-HD ANP level may be a reliable parameter for assessing the risk for cardiac death in HD patients by providing prognostic information independent of other variables previously reported."
01/01/2003 - "By stepwise multivariate Cox proportional hazards analysis, only ANP, LVMI and CRP remained powerful independent predictors of cardiac death. "
01/01/2003 - "When compared with patients with ANP <50, the hazard ratios for cardiac death of patients with ANP of >50 pg/ml were 32.0 (95% confidence interval (CI) 4.1 to 252.4). "
01/01/2003 - "Although the plasma ANP is a prognostic predictor of cardiac death, the prognostic role of ANP in HD patients has yet to be elucidated. "
09/01/2009 - "A significantly higher incidence of cardiac death was noted amongst smokers and patients with elevated total cholesterol. "
01/01/2008 - "Lowering serum cholesterol has been shown to reduce coronary events, cardiac death, and total mortality among high risk patients. "
01/01/1997 - "The relative risk of non-cardiac death was 2.27 times higher in the low cholesterol group than in the controls (95% CI: 1.49-3.45), whereas the risk of cardiac death was the same in both groups (relative risk 1.09; 95% CI: 0.76-1.56). "
01/01/1993 - "The objective of this study was to measure cholesterol concentrations in diabetic patients at the beginning of maintenance hemodialysis treatment and to define their role as predictors of subsequent cardiac death on maintenance hemodialysis. "
01/01/1997 - "These results in patients with coronary heart disease add weight to previous studies associating low total cholesterol with an increased risk of non-cardiac death. "
06/01/2011 - "Although placing lungs obtained via donation after cardiac death is more difficult because of a multitude of factors, the transplant coordinators, in conjunction with the transplant center, overcame several obstacles in order to transplant the lungs with good outcomes so far. "
04/01/2012 - "Short- and long-term HMP has been shown to improve graft viability and reduce preservation injury, even in animal models of steatotic and donation after cardiac death. "
10/01/2011 - "Grafts from donors after cardiac death show promise in expanding the donor pool. "
06/01/2015 - "This study was conducted to evaluate the outcomes of single kidney transplant from pediatric donors in China younger than 5 years old after cardiac death. "
10/01/2013 - "The aim of this study was to assess the functional preservation of the lung graft with anterograde lung perfusion in a model of donation after cardiac death. "
|2.||Transplantation (Transplant Recipients)
09/01/2013 - "After intensive medical therapy, a 50% increase in baseline serum sACE2 levels predicted a significant reduction in risk of death, cardiac transplantation, or ADHF rehospitalization, including after adjustment for baseline age, RAVi, and BNP levels (hazard ratio 0.35, 95% confidence interval 0.12-0.84; P = .018). "
02/01/2007 - "There have been substantial changes in preoperative selection and preparation of lung transplant recipients; these include donation after cardiac death, and improved lung-preservation solutions. "
01/01/2015 - "All patients underwent right heart catheterization and were followed until death, cardiac transplantation, or the end of the study period (mean time 4.4 years). "
01/01/2014 - "The purpose of this study was to investigate the current attitudes trend and characteristics of transplantation with organs donated after cardiac death in northwest China. "
02/01/2011 - "This study provides the first evidence that pretreatment of the donor with a single pharmacologically relevant dose of EPO causes substantial attenuation of the dysfunction and injury associated with the transplantation of kidneys recovered after cardiac death."
07/01/2006 - "The relation between collaterals and cardiac death or MI at 1 year after coronary revascularization was studied in 561 patients who were enrolled in a randomized study that compared stent implantation with bypass grafting. "
01/01/2014 - "Adjusted risks showed no significant differences between stent types for cardiac death, MI and TVR. "
11/01/2013 - "Pathologic findings of coronary stents: a comparison of sudden coronary death versus non-cardiac death."
02/01/2011 - "Secondary outcomes were the composite of cardiac death, MI or target lesion revascularisation (TLR), and individual outcomes including ST. A total of 4,939 patients received ≥1 Genous stent between 2005 and 2007. "
09/15/2010 - "The cumulative late effect of TLR after drug-eluting or bare metal stent placement on cardiac death or MI is uncertain. "
12/01/2012 - "• The protective effects of H(2) S suggest potential clinical applications in both donors after cardiac death models of renal transplantation and oncological practices requiring vascular clamping."
03/01/2007 - "Improved outcomes of renal transplantation from cardiac death donors: a 30-year single center experience."
02/01/2014 - "The feasibility of an experimental model of donors after cardiac death in remote ischemic preconditioning studies for renal transplantation in porcine."
01/01/2012 - "The aim of this study was to investigate factors that may improve the condition of a marginal kidney preserved with a normothermic solution following cardiac death (CD) in a model of rat kidney transplantation (RTx). "
01/01/2010 - "The purpose of this study was to report the Dutch experience of kidney transplantation using pediatric donation after cardiac death. "
|5.||Angioplasty (Angioplasty, Transluminal)
04/01/1998 - "In patients with MI treated with thrombolysis or primary angioplasty, radionuclide ventriculography may be helpful in identifying patients at low risk for subsequent cardiac death. "
05/01/1999 - "Five-year rates of death, cardiac death, repeat revascularization and angina were similar in all angioplasty patients with IR versus CR intended. "
09/01/1996 - "Follow-up data (23 +/- 17 months) showed a higher but not significant rate of coronary events (cardiac death, reinfarction, severe angina, coronary bypass or angioplasty) in Group A patients with a positive test (62 vs 39% in Group B); however, in the subgroup with homozonal positive test, the event rate was much higher in Group A (77 vs 18% in Group B; p < 0.01). "
07/15/1996 - "At a mean follow-up of 6.1 +/- 4.1 months, there was 1 additional cardiac death, and no patient had AMI or required repeat coronary angioplasty or bypass; among the 29 survivors, 86% were free of angina. "
02/01/1988 - "Thus, cardiac death after elective coronary angioplasty is very rare in experienced centers and occurs most often in women with a large amount of potentially ischemic myocardium. "